Lumakras is the next test of FDA’s hardening stance
After Exkivity signals another accelerated approval slowdown the Amgen drug tomorrow faces an adcom over its own conditional approval.
ESMO 2023 preview – J&J pulls a Mariposa rabbit out of the hat
And there won’t be a long to wait for the full data, with revelation that Mariposa features among numerous practice-changing late-breakers at ESMO.
12 years on, Jakafi faces serious JAK competition
Momelotinib gains full US approval in a broader setting than expected, validating GSK’s $1.9bn buyout of Sierra Oncology.
Bristol seeks novelty in TIGIT
Disclosure of BMS-986442’s second target antigen endorses Agenus, and is highly relevant for GSK and Compugen too.
No keeping the red light on for Sting
CuraDev and OncoNano move into phase 1, trying to avoid the negative precedent of other Sting agonist projects.
Despite the setbacks, interest in TGF-β remains
Novartis looks set to hand nisevokitug rights back to Xoma, though plenty of work on TGF-β continues.
US approval gives Jemperli a treatment niche
However, endometrial cancer remains a small use, and Jemperli has other ways to make a bigger splash.
